Assocaiton Between Uric Acid Trajecteries and Remission of NAFLD in NAFLD Individuals

Non-Alcoholic Fatty Liver Disease Clinical Trial

Official title:

Assocaiton Between Uric Acid Trajecteries and Remission of Non-alcoholic Fatty Liver Disease (NAFLD) in NAFLD Individuals

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05245890
• Other study ID #: uric acid trajecteries2022
• Status: Not yet recruiting
• Start date: March 1, 2022
• Est. completion date: March 1, 2024

Study information

• Verified date: February 2022
• Source: Ningbo No. 1 Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders. A growing body of evidence, comprising a great deal of cross-sectional studies and several prospective ones, also indicates that hyperuricemia is associated with increased prevalence, incidence, and disease severity of non-alcoholic fatty liver disease (NAFLD). Capitalizing on a cohort study in China, the investigators are aimed to assess the associations of SUA trajecteries with remission of NAFLD in NAFLD individuals and examined whether the association differs across subpopulations.

Description:

A cohort study was conducted to evaluate the relationship between the SUA trajecteries and remission of NAFLD. The study enrolled employees who were attending their annual health examination. Furrhermore, the investigators are aimed to explore whether the association differs across subpopulations.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 2000
• Est. completion date: March 1, 2024
• Est. primary completion date: March 1, 2023
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. age >=18 years;

2. agree to be enrolled in this study.

Exclusion Criteria:

1. those taking antihypertensive or antidiabetic agents, lipid-lowing agents, or hypouricemic agents;

2. those with alcohol consumption greater than 140 g/week for men and 70 g/week for women;

3. those with a history of other known causes of chronic liver disease such as viral hepatitis or autoimmune hepatitis, and those using hepatotoxic medications.

Related Conditions & MeSH terms

• Fatty Liver
• Hyperuricemia
• Liver Diseases
• Non-Alcoholic Fatty Liver Disease

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Ningbo No. 1 Hospital	The First Afliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the severity fatty liver evaluated by hepatic ultrasonic examination	Hepatic ultrasonic examination was performed in all subjects by a trained ultrasonographist who was unaware of the clinical and laboratory data. Hepatic steatosis was diagnosed by characteristic echo patterns according to conventional criteria, such as the evidence of diffuse hyperechogenicity of the liver relative to the kidneys, ultrasound beam attenuation, and poor visualization of intrahepatic structures.	2 years